Todd Asset Management LLC Lowers Position in ICON Public Limited (NASDAQ:ICLR)

Todd Asset Management LLC trimmed its stake in ICON Public Limited (NASDAQ:ICLR) by 32.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,620 shares of the medical research company’s stock after selling 24,339 shares during the period. Todd Asset Management LLC owned approximately 0.06% of ICON Public worth $14,046,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bruce G. Allen Investments LLC bought a new stake in ICON Public in the 4th quarter worth approximately $25,000. Pinnacle Bancorp Inc. boosted its stake in shares of ICON Public by 110.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 55 shares in the last quarter. GAMMA Investing LLC purchased a new stake in shares of ICON Public in the 4th quarter valued at $37,000. NBC Securities Inc. bought a new position in shares of ICON Public during the 3rd quarter valued at $174,000. Finally, Motco raised its position in ICON Public by 766.4% in the 3rd quarter. Motco now owns 1,291 shares of the medical research company’s stock worth $318,000 after purchasing an additional 1,142 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

ICON Public Stock Performance

Shares of ICON Public stock traded up $7.95 during trading on Friday, hitting $309.02. 567,325 shares of the company’s stock traded hands, compared to its average volume of 557,736. ICON Public Limited has a 1 year low of $181.92 and a 1 year high of $344.77. The business has a 50-day simple moving average of $319.47 and a 200-day simple moving average of $284.79. The stock has a market capitalization of $25.49 billion, a P/E ratio of 37.59, a PEG ratio of 1.36 and a beta of 1.18. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.21 and a quick ratio of 1.21.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, February 21st. The medical research company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. As a group, analysts forecast that ICON Public Limited will post 14.41 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Robert W. Baird raised their target price on shares of ICON Public from $362.00 to $363.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Truist Financial increased their target price on shares of ICON Public from $357.00 to $367.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Mizuho restated a “buy” rating and set a $346.00 price target on shares of ICON Public in a report on Thursday, April 4th. TD Cowen upped their price target on ICON Public from $343.00 to $349.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, Evercore ISI cut their price objective on ICON Public from $350.00 to $330.00 and set an “outperform” rating on the stock in a research report on Friday, April 26th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $339.44.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.